Scienture Holdings, Inc. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Scienture Holdings (market cap ~$10.2M) reported Q2 2026 revenue of $343,639 (vs. $56,325 in Q1 2026, a 510% sequential jump) and H1 2026 revenue of $399,964 (vs. $10,258 in H1 2025). Q2 2026 gross margin was 97.7% on gross profit of $335,779. Operating loss improved 48% YoY to $2.7M; net loss narrowed 58% YoY to $2.8M. Cash increased to $11.2M (including $3M restricted) from $6.7M at year-end 2025. The company commenced commercial launch of REZENOPY (naloxone nasal spray) in Q3 2026, its second FDA-approved product alongside ARBLI (losartan suspension), and secured formulary coverage with a major national health plan.
Why this rating
Revenue inflection and profitability path credible for $10.2M-cap firm; new product launch and payer coverage expansion material; cash burn trajectory improving materially.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.